Fosun Pharma invests in Sinopharm, appoints new executives

Shanghai Fosun Pharmaceutical Group (SSE:600196) is bolstering its strategic investments and leadership team, while one executive is departing. The company's Board of Directors approved a capital injection of CNY 270 million into Sinopharm, alongside International Finance Corporation (IFC) and Asian Development Bank (ADB), with the goal to enhance capital and operational capabilities of Sinopharm. Post-investment, Fosun Pharma will hold 20.05% stake in Sinopharm. Separately, Fosun Pharma has appointed Xiang Li and Zhou Xudong as senior vice presidents, both for terms beginning March 31, 2025. Prior to joining Fosun Pharma, Xiang Li served as a chief scientific officer at Bioduro-Sundia and Zhou Xudong was vice president at Sinopharm Holdings. Additionally, it was announced that Bao Qingui resigned from his role as senior vice president of Fosun Pharma, effective March 31, 2025.